

SPN

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re Patent Application of

Deborah Kim GLENCROSS

Application No.: 10/754,711

Filing Date: January 12, 2004

Title: ENUMERATION OF CD4+
LYMPHOCYTES (AS AMENDED)

)
)
) Group Art Unit: 1651
)
) Examiner: A. FORD
)
) Confirmation No.: 1340
)
)
)
)
)

FIRST
INFORMATION DISCLOSURE STATEMENT
TRANSMITTAL LETTER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Enclosed is a FIRST Information Disclosure Statement (IDS) Form PTO-1449 and 18 Cited References for the above-identified patent application.

- ☐ No additional fee for submission of an IDS is required.
- ☐ The fee of 180 as set forth in 37 C.F.R. § 1.17(p) is also enclosed.
- ☐ A statement under 37 C.F.R. § 1.97(e) is also enclosed.
- ☐ A statement under 37 C.F.R. § 1.97(e), and the fee of 180 as set forth in 37 C.F.R. § 1.17(p) are also enclosed.
- ☐ Charge _____ to Deposit Account No. 02-4800 for the fee due.
- ☐ A check in the amount of _____ is enclosed for the fee due.
- ☐ Charge _____ to credit card for the fee due. Form PTO-2038 is attached.
- ☒ The Director is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BUCHANAN INGERSOLL AND ROONEY PC

Date December 7, 2006

By:

Deborah H. Yellin
Deborah H. Yellin
Registration No. 45,904

P.O. Box 1404
Alexandria, VA 22313-1404
703 836 6620



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inter Patent Application of

Deborah Kim GLENCROSS

Application No.: 10/754,711

Filed: January 12, 2004

For: ENUMERATION OF CD4+
LYMPHOCYTES (AS AMENDED)

)
)
) Group Art Unit: 1651
)
) Examiner: A. FORD
)
) Confirmation No.: 1340
)
)
)
)
)
)

FIRST INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, the accompanying information is being submitted in accordance with 37 C.F.R. §§ 1.97 and 1.98.

Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed.

The information is submitted before the mailing of a first Office Action after the filing of a Request for Continued Examination under 37 C.F.R. § 1.114.


To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

Respectfully submitted,

BUCHANAN INGERSOLL & ROONEY PC

Date: December 7, 2006

By:


Deborah H. Yellin
Registration No. 45,904


P.O. Box 1404
Alexandria, VA 22313-1404
703 836 6620

FIRST
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Application Number	10/754,711
Filing Date	January 12, 2004
First Named Inventor	Deborah Kim GLENCROSS
Examiner Name	A. FORD
Attorney Docket No.	1025455-000113



U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Issue/Publication Date (MM-DD-YYYY)

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Kind Code (if known)	Country	Date of Publication (MM-DD-YYYY)	STATUS						
					Translation	Partial Translation	Eng. Lang. Summary	Search Report	IPER	Abstract	Cited in Spec

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	Ian Storie et al., "Flow Rate Calibration II: A Clinical Evaluation Study Using PanLeucoGating as a Single-Platform Protocol", Clinical Cytometry, 55B:8-13 (2003).
	D.K. Glencross et al., "Results from the WHO/NHLS/QASI CD4 Regional External Quality Assessment Scheme (REQAS): Multi-Site Evaluation of CD4 Technology Performance", 2 nd South African AIDS Meeting, June 2005.
	W. Stevens et al., "Affordable HIV Diagnosis and Monitoring for Scaling Up ARV Treatment Programmes", The Southern African Journal of HIV Medicine, September 2005, pages 38-41.
	L. Scott et al., "Monitoring Reproducibility of Single Analysis, Single Platform CD4 Cell Counts in a High Volume, Low Resource Laboratory Setting Using Sequential Bead Count Rates", Clinical Cytometry, 67B:31-32 (2005).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FIRST
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

Application Number	10/754,711
Filing Date	January 12, 2004
First Named Inventor	Deborah Kim GLENCROSS
Examiner Name	A. FORD
Attorney Docket No.	1025455-000113

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	T. Rehle et al., "HIV-positive educators in South African public schools", Education Labour Relations Council, 2005.
	T. Rehle et al., "Appendix and Addenda - HIV-positive educators in South African public schools", Education Labour Relations Council, 2005.
	NCCLS, "Clinical Applications of Flow Cytometry: Quality Assurance and Immunophenotyping of Lymphocytes; Approved Guideline", 1998.
	U.S. Food and Drug Administration, "Recognized Consensus Standards", www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfstandards/detail.CFM?Standard_identification_NO-10448 .
	G. Vercauteren et al., "Impact of Who External Quality Assessment (EQA) programme on the laboratory performance of CD4 enumeration for monitoring of ARV therapy in Resource Limited settings", World Health Organization, Conference: AIDS2006 (Abstract).
	D. Glencross et al., "Improved between-laboratory performance of South African NHLS laboratories using PLG CD4 methodology for the national antiretroviral (ARV) treatment programme", University of the Witwatersrand, August 14, 2006 (Abstract).
	D. Glencross et al., "CD45-Assisted PanLeucogating for Accurate, Cost-Effective Dual-Platform CD4+ T-Cell Enumeration", Cytometry (Clinical Cytometry) 50: 69-77 (2002).
	M. Willja et al., "Less Expensive CD4+ T Cell Monitoring Using Panleucogating", AIDS 2002 Barcelona, July 7-12, 2002 (Abstract).
	K. Pattanapanyasat et al., "A Multicenter Evaluation of the PanLeucogating Method and the Use of Generic Monoclonal Antibody Reagents for CD4 Enumeration in HIV-Infected Patients in Thailand", Cytometry Part B (Clinical Cytometry) 65B: 29-36 (2005).
	K. Pattanapanyasat et al., "Low-Cost CD4 Enumeration in HIV-Infected Patients in Thailand", Asian Pacific Journal of Allergy and Immunology, 21: 105-113 (2003).
	T. Denny et al., "Determination of CD4 and CD8 Lymphocyte Subsets by a New Alternative Fluorescence Immunoassay", Clinical and Diagnostic Laboratory Immunology, May 1995, p. 330-336.
	L. Scott et al., "Antiviral Therapy 8 (suppl 1) Abstract No. 1226", 2 nd International AIDS Conference on HIV Pathogenesis and Treatment, France, 2003.
	T. Denny et al., "A Multi-Lab Study of CD4 Counts Using Flow Cytometric PanLeukoGating (PLG): A Niaid-Daids Immunology Quality Assessment Program Study", 13 th Conference Retrovirology and Opportunistic Infection (CROI), Boston, Feb. 2006.
	N. Sippy et al., "Comparison of the Panleucogating technique with four-color heterogenous gating for CD4+ T cell enumeration by flowcytometry in HIV-1 infected individuals in Barbados", Ladymeade Reference Unit, Ministry of Health, Barbados.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.